The germany hyaluronic acid products market is on an impressive growth trajectory, with projections estimating its value to reach USD 632.4 million by 2025. Fueled by increasing demand across ...

Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $240.00. The company’s shares closed yesterday at ...

The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). Financial Milestones: AbbVie's Journey Market Capitalization Analysis: With an elevated ...

AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie will lead development ...

AbbVie’s Allergan Aesthetics division has a presence in targeted fat reduction with CoolSculpting, a nonsurgical medical device. The company does not market this offering as a treatment for ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. President Donald Trump’s first month in office has been dizzying for U.S ...

We recently published a list of 10 Best DRIP Stocks To Own Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best DRIP stocks to own now.